RSPI (RespireRx Pharmaceuticals) Beta: 0.2138 (As of Jul. 10, 2026)


RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals Beta?

RespireRx Pharmaceuticals RSPI 12 Beta is 0.2138 as of Jul. 10, 2026. GuruFocus rates RSPI with a GF Score™ of 12/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-10), RespireRx Pharmaceuticals's Beta is 0.2138.


RespireRx Pharmaceuticals  (OTCPK:RSPI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


RespireRx Pharmaceuticals Beta Related Terms


RespireRx Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Beta Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 -0.41 0.12 0.59 0.28

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.28 -0.07 -0.02 -0.03

RSPI vs CNBX, NAVB, IPIX: Beta Comparison

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RespireRx Pharmaceuticals Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Beta falls into.


RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2138 mean?
RespireRx Pharmaceuticals (RSPI) has a Beta of 0.2138 as of Jul. 10, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' Beta too high?
RespireRx Pharmaceuticals' current Beta is 0.2138. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' Beta compare to CNBX and NAVB?
RespireRx Pharmaceuticals' Beta of 0.2138 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current Beta is 0.2138. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current Beta of 0.2138. The current Beta is 0.2138. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Beta is 0.2138 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price